Longitudinal Systemic Corticosteroid Utilisation for Asthma and Other Diseases in the United Kingdom from 1990 to 2018: A Population-based Cohort Analysis

Jaco Voorham; Andrew Menzies-Gow; Trung N Tran; Victoria Carter; Josef S  Smolen; Arnaud Bourdin; Jatin  Chapaner; Benjamin  Emmanuel; David J Jackson; David B Price

Longitudinal Systemic Corticosteroid Utilisation for Asthma and Other Diseases in the United Kingdom from 1990 to 2018: A Population-based Cohort Analysis

Jaco Voorham
, Andrew Menzies-Gow
, Trung N Tran
, Victoria Carter
, Josef S Smolen
, Arnaud Bourdin
, Jatin Chapaner
, Benjamin Emmanuel
, David J Jackson
, David B Price

Data To Insights Research Solutions
Royal Brompton Hospital
Observational and Pragmatic Research Institute Singapore
Medical University of Vienna
AstraZeneca, Gaithersburg
King's College London
Observational & Pragmatic Research Institute Pte Ltd
AstraZeneca
Université de Montpellier

Research output: Contribution to conference › Abstract › peer-review

37 Downloads (Pure)

Abstract

Evidence of increased adverse event risk with systemic corticosteroid (SCS) use led patient management guidelines to embrace SCS-sparing treatment strategies. This study was conducted to describe time trends in SCS prescriptions and their relation to National Health Service (NHS) availability of SCS-sparing therapies.

Original language	English
Number of pages	3
Publication status	Published - 19 Feb 2021
Event	BTS WINTER MEETING - Online Duration: 17 Feb 2021 → 20 Feb 2021 https://www.brit-thoracic.org.uk/education-and-events/winter-meeting-online/

Conference

Conference	BTS WINTER MEETING
Period	17/02/21 → 20/02/21
Internet address	https://www.brit-thoracic.org.uk/education-and-events/winter-meeting-online/

Bibliographical note

Funding: This work was supported by AstraZeneca.

Access to Document

Voorham_et_al_BTSWM2021_LongitudinalSystemicCorticosteroid_AAM
© Authors (or their employer(s)) OR “© BMJ Publishing Group Ltd” ( for assignments of BMJ Case Reports) “ 2021” [Add where a funder mandates: “Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) http://creativecommons.org
Accepted author manuscript, 276 KBLicence: CC BY-NC

Cite this

@conference{443925e971d04576af80a0344e62941d,

title = "Longitudinal Systemic Corticosteroid Utilisation for Asthma and Other Diseases in the United Kingdom from 1990 to 2018: A Population-based Cohort Analysis",

abstract = "Evidence of increased adverse event risk with systemic corticosteroid (SCS) use led patient management guidelines to embrace SCS-sparing treatment strategies. This study was conducted to describe time trends in SCS prescriptions and their relation to National Health Service (NHS) availability of SCS-sparing therapies. ",

author = "Jaco Voorham and Andrew Menzies-Gow and Tran, \{Trung N\} and Victoria Carter and Smolen, \{Josef S\} and Arnaud Bourdin and Jatin Chapaner and Benjamin Emmanuel and Jackson, \{David J\} and Price, \{David B\}",

note = "Funding: This work was supported by AstraZeneca.; BTS WINTER MEETING ; Conference date: 17-02-2021 Through 20-02-2021",

year = "2021",

month = feb,

day = "19",

language = "English",

url = "https://www.brit-thoracic.org.uk/education-and-events/winter-meeting-online/",

}

TY - CONF

T1 - Longitudinal Systemic Corticosteroid Utilisation for Asthma and Other Diseases in the United Kingdom from 1990 to 2018

T2 - BTS WINTER MEETING

AU - Voorham, Jaco

AU - Menzies-Gow, Andrew

AU - Tran, Trung N

AU - Carter, Victoria

AU - Smolen, Josef S

AU - Bourdin, Arnaud

AU - Chapaner, Jatin

AU - Emmanuel, Benjamin

AU - Jackson, David J

AU - Price, David B

N1 - Funding: This work was supported by AstraZeneca.

PY - 2021/2/19

Y1 - 2021/2/19

N2 - Evidence of increased adverse event risk with systemic corticosteroid (SCS) use led patient management guidelines to embrace SCS-sparing treatment strategies. This study was conducted to describe time trends in SCS prescriptions and their relation to National Health Service (NHS) availability of SCS-sparing therapies.

AB - Evidence of increased adverse event risk with systemic corticosteroid (SCS) use led patient management guidelines to embrace SCS-sparing treatment strategies. This study was conducted to describe time trends in SCS prescriptions and their relation to National Health Service (NHS) availability of SCS-sparing therapies.

UR - https://www.brit-thoracic.org.uk/education-and-events/winter-meeting-online/

M3 - Abstract

Y2 - 17 February 2021 through 20 February 2021

ER -

Longitudinal Systemic Corticosteroid Utilisation for Asthma and Other Diseases in the United Kingdom from 1990 to 2018: A Population-based Cohort Analysis

Abstract

Conference

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this